Absci(US:ABSI) Globenewswire·2026-03-24 20:05Core Insights - Absci Corporation has successfully dosed the first three cohorts in the single ascending dose (SAD) portion of its ongoing Phase 1/2a HEADLINE trial for ABS-201, which has shown favorable emerging safety data [1][5] - The company appointed Dr. Ransi Somaratne as Chief Medical Officer to lead clinical execution and strategy [1][2] - Absci's cash, cash equivalents, and marketable securities are sufficient to fund operations into the first half of 2028 [1][7] Clinical Development - ABS-201 is being developed for androgenetic alopecia (AGA) and endometriosis, addressing significant unmet medical needs in both areas [2][6] - The company plans to deliver interim proof-of-concept data for ABS-201 in the second half of 2026 and initiate a Phase 2 trial for endometriosis by year-end 2026 [2][6] - ABS-201 has demonstrated the ability to stimulate hair growth and regenerate the follicle stem cell niche, with significant inhibition of the PRLR signaling pathway [5][6] Financial Performance - For Q4 2025, Absci reported revenue of $0.7 million, unchanged from Q4 2024 [8] - Research and development expenses increased to $25.3 million in Q4 2025 from $18.4 million in Q4 2024, primarily due to advancements in internal programs [9] - The net loss for Q4 2025 was $29.6 million, compared to a net loss of $29.0 million in Q4 2024 [11] Annual Financial Results - For the full year 2025, Absci reported revenue of $2.8 million, down from $4.5 million in 2024 [12] - Research and development expenses rose to $81.4 million in 2025 from $63.9 million in 2024 [12] - The net loss for the full year 2025 was $115.2 million, compared to a net loss of $103.1 million in 2024 [15] Pipeline and Future Outlook - Absci continues to explore potential partnerships and outlicensing opportunities for its programs, including ABS-101 and ABS-301 [14] - The company anticipates signing one or more drug creation partnerships in 2026, including with a large pharmaceutical company [14]